Sarepta’s Exondys Successor Bounces Back From Clinical Hold But All Eyes On Gene Therapy

The firm’s exon-skipping Duchenne muscular dystrophy asset will resume clinical study in the US following the lifting of a clinical hold but observers seem more invested in the fate of its gene therapy candidate for the condition.